论文部分内容阅读
目的探析子宫肌瘤患者用不同剂量米非司酮治疗对其病情改善的差异性。方法纳入本院2016年-2017年期间收治确诊子宫肌瘤患者相关临床资料,所有患者均用米非司酮治疗,从中抽取80例根据所用剂量异常将患者每组40例分为A组、B组,分别对应大剂量、小剂量米非司酮治疗。疗程后对比不同剂量对患者的治疗效果。结果记录患者疗程后各项指标,包括:子宫体积、血红蛋白、病灶体积,相对于治疗前患者各指标均有所改善,B组更具优越性,统计学存在意义(P<0.05);随访期间,B组患者出现药物相关不良反应例数明显低于A组,数据差异统计学存在意义(P<0.05)。结论米非司酮对子宫肌瘤病情有改善作用,选择小剂量给药方式不仅对患者病情有更积极的影响,同时安全性相对大剂量用药更高,值得临床推广。
Objective To investigate the difference of improvement of the condition of patients with uterine fibroids treated with different doses of mifepristone. Methods included in our hospital from 2016 to 2017 admitted to the diagnosis of uterine fibroids related to clinical data, all patients were treated with mifepristone, 80 patients were selected according to the dose of abnormalities in each group of 40 patients were divided into A group, B Group, corresponding to high-dose, low-dose mifepristone treatment. After treatment contrast different doses of the treatment of patients. Results The indexes of patients after treatment were recorded, including: uterine volume, hemoglobin, volume of lesions, relative to all patients before treatment were improved, group B more advantages, statistically significant (P <0.05); during follow-up The number of drug-related adverse reactions in group B was significantly lower than that in group A (P <0.05). Conclusions Mifepristone can improve the condition of uterine leiomyoma. The choice of low-dose administration not only has a more positive impact on the patient’s condition, but also has higher safety and higher dosage, which is worthy of clinical promotion.